Aprea Therapeutics, Inc.
APRE
$1.59
-$0.0324-2.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 23.49% | -9.04% | -23.49% | 18.39% | -7.45% |
| Total Depreciation and Amortization | 0.00% | 1.89% | -14.52% | 24.00% | 257.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.98% | 37.76% | 351.18% | -81.61% | 104.69% |
| Change in Net Operating Assets | -162.94% | 462.01% | 73.24% | -150.94% | -152.47% |
| Cash from Operations | -42.24% | 32.22% | 7.48% | -5.25% | -66.80% |
| Capital Expenditure | -- | 100.00% | 6.25% | -11.11% | 91.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 6.25% | -11.11% | 91.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -433.33% | 94.31% | 98.36% | -- | -- |
| Cash from Financing | 11,300.00% | 94.31% | -100.14% | -- | -- |
| Foreign Exchange rate Adjustments | -199.60% | 614.58% | -100.00% | -700.00% | 111.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.12% | 33.47% | -134.14% | 387.30% | -60.70% |